How Intelligencia AI revolutionizes drug development with AI, with Dimitris Skaltsas
About this episode
What does it take to innovate at the crossroads of technology and life sciences?
This week we are joined by Dimitris Skaltsas, Co-Founder and CEO of Intelligencia AI, an innovative company applying AI and machine learning to de-risk drug development. Intelligencia AI aims to bridge the gap between innovation and risk reduction with an interdisciplinary team of software engineers, AI practitioners, scientists, and drug developers, with the ultimate goal of bringing novel therapies to patients faster.
Dimitris shares insights into balancing innovation with regulation, releasing AI tools at the right moment, and fostering trust-based relationships to bridge the gap between risk and discovery.
🚀Listen to Dimitris discuss how to think fast and slow in start-up culture
https://www.youtube.com/watch?v=HDLq4kdMy9o
Learn more about EUROPE BUILDS: https://byborrn.substack.com/p/does-europe-build-real-innovation
Get every episode summarized
Each time EUROPE BUILDS by BORRN publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from EUROPE BUILDS by BORRN
What Europe’s next generation of founders is building right now
EUROPE BUILDS by BORRN
How to lead with product intuition—not just data
EUROPE BUILDS by BORRN
How to invest in outliers, not consensus
EUROPE BUILDS by BORRN
How Native Teams is rethinking global work
EUROPE BUILDS by BORRN